title: Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
abstract: OBJECTIVE
  Single-dose nevirapine (sd-NVP) for prevention of mother-to-child HIV-1 transmission is associated with selection of resistant viral variants, particularly the Lysine (K) to Asparagine (N) mutation at codon 103 (K103N) of reverse transcriptase. As this may influence subsequent treatment responses, a better understanding of the dynamics of decay and persistence of this variant is needed.
  
  
  METHODS
  We measured the frequency of K103N mutants among a cohort of HIV-1-infected pregnant women recruited at an out-patient clinic in Johannesburg, South Africa. Samples taken 6 weeks, 3, 7 and 12 months after delivery from 67 HIV-1-infected women who received sd-NVP during labor to prevent transmission were analyzed. Quantification of K103N mutants in maternal plasma viral RNA and cellular DNA was done using an allele-specific real-time polymerase chain reaction assay capable of detecting codons AAC and AAT if their frequency was > 0.002 of the total viral population.
  
  
  RESULTS
  Using the allele-specific assay, 87.1% (27/31) of RNA samples and 52.3% (23/44) of DNA samples collected 6 weeks after sd-NVP had detectable K103N variants. This declined to 65.4% (17/26), 38.9% (14/36), and 11.3% (6/53) in RNA at 3, 7 and 12 months respectively, and to 4.2% (2/48) in DNA at 12 months.
  
  
  CONCLUSIONS
  K103N resistant variants were present in almost all women at 6 weeks post-sd-NVP but declined rapidly over time. Resistant variants were detected less frequently in cellular DNA with persistence in this compartment by 12 months post-sd-NVP among only a minority.
authors.affiliation: AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa.
authors.forename: Shayne
authors.initials: S
authors.lastname: Loubser
authors.forename: Peter
authors.initials: P
authors.lastname: Balfe
authors.forename: Gayle
authors.initials: G
authors.lastname: Sherman
authors.forename: Scott
authors.initials: S
authors.lastname: Hammer
authors.forename: Louise
authors.initials: L
authors.lastname: Kuhn
authors.forename: Lynn
authors.initials: L
authors.lastname: Morris
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D004279:DNA, Viral / Q000032:analysis; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D015658:HIV Infections / Q000235:genetics / Q000517:prevention & control / Q000635:transmission*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008137:Longitudinal Studies; D009154:Mutation; D019829:Nevirapine / Q000008:administration & dosage*; D016133:Polymerase Chain Reaction / Q000379:methods; D011247:Pregnancy; D012367:RNA, Viral / Q000097:blood; D013997:Time Factors
chemical_list: D019380:Anti-HIV Agents; D004279:DNA, Viral; D012367:RNA, Viral; D019829:Nevirapine